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Abstract The high regioselectivity associated with the Ir-catalyzed borylation of 
pyridones has been exploited to provide a very direct and efficient entry to 
C(10) doubly substituted CC4 variants of cytisine.  Two approaches have been 
evaluated based on (i) C–H activation of cytisine (or an N-substituted 
derivative) followed by N-alkylation (to enable dimer formation) and (ii) direct 
C-H activation and borylation of CC4 itself.  Both approaches provide access to 
C(10)-functionalized CC4 derivatives, but direct borylation of CC4 allows for a 
wider range of functional group interconversions to be tolerated. 
Key words 2-Pyridone, iridium-catalyzed borylation, C‒H functionalization, 
CC4, cytisine. 
 
The Ir-catalyzed borylation of arenes and heteroarenes offers a 
very direct entry to boronic esters that underpins a wide range of 
effective synthetic transformations.1 With arenes, C‒H activation 
process is generally sterically controlled, but within 
heteroarenes electronic effects (e.g. relative acidity) of 
competing C‒H sites influences the regiochemical outcome.2  
Pyridines and related heterocycles have received attention,3 and 
the recent publication of Hirano and Miura4 describing 
Ir-catalyzed borylation of 2-pyridones prompts us to report our 
related results in this area.   
Pyridones, which offer a predictable but constrained selectivity 
for electrophilic substitution at C(3) and C(5), have added 
complexity: two potential metal binding sites associated with the 
substrate.  In earlier work, Hirano and Miura5 exploited an 
N-pyridyl moiety as a directing function (to functionalize at C(6)) 
but otherwise access to pyridone-based boronic esters relies on 
electrophilic halogenation as a key step.6  As a consequence, 
direct C‒H functionalization offers an opportunity to extend 
significantly the range of pyridone substitution patterns 
available.  
We had carried out broadly the same study of both simple and 
more complex 2-pyridones to determine basic reactivity patterns 
as described by Hirano and Miura.4 Our results paralleled those 
reported earlier although we assessed product distribution (and 
reaction efficiency) following in situ bromination7 of the initial 
Bpin ester to give bromopyridones 2-5 (Scheme 1, Table 1).  
There were, however, differences in terms of the approach we 
have used which we note here.  In our hands, for example, the 
parent 2-pyridone 1a was unreactive8 towards C‒H activation; 
we observed no conversion under our standard conditions where 
we used dtbpy as the bipyridyl ligand. More generally, and based 
on our experience with related substrates, the presence of an 
acidic NH (as in 1a) inhibits Ir-catalyzed borylation. 
 
Scheme 1 Ir-Catalyzed borylation/in situ bromination7 of simple 2-pyridones.  
Table 1 Regiochemistry of C‒H activation in simple 2-pyridones. 
Substrate Conversion 2:3:4:5[a] Isolated yields[b] 
1a R = H 0%[c] - No conversion observed 
1b R = Me 100% 5:35:39:21 2b+3b (38%); 4b (22%); 5b 
(11%) 
1c R = Bu ≥90% 26:53:6:15 2c + 3c (69%); 5c (10%) 
1d R = Bn ≥90% 35:65:0:0 2d + 3d (83%)  
1e R = Boc 0%[c] - No conversion observed 
[a]Product ratios, following in situ bromination7 were based on 1H NMR; see text and 
Supporting Information. [b]Monobromo isomers 2 and 3 were inseparable by 
chromatography and the combined yield is shown. [c]see text.8,9 
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Within the simple pyridone series shown in Scheme 1, some level 
of double C‒H activation was also observed (via dibrominated 
products 4 and 5) but consistently C(5) substitution (3 + 5) was 
preferred over C(4) (2 + 4).  Double insertion observed was a 
result of C–H activation/borylation rather than an additional 
bromination occurring in step 2 (Scheme 1) 9 and the proportion 
of dibrominated adducts observed appears to link to the size of 
the N-substituent (compare products from 1b vs. 1c vs. 1d).  
Interestingly, the N-benzyl variant 1d gave only pyridone 
substitution with no indication that borylation of the N-benzyl 
residue was competitive; however, see below. The N-Boc variant 
1e failed to react but the issue here was that rapid N-Boc cleavage 
occurred under the reaction conditions (based on 1H NMR 
analysis) releasing the unreactive parent 2-pyridone 1a. 
Our primary interest in this area has, however, been on the 
application of this C-H activation process to the development of 
novel heterocyclic ligands that are specific for the 42 nicotinic 
acetylcholine receptor (nAChR).10 This subtype is the high 
affinity nicotine receptor and, with smoking responsible for some 
7 million deaths annually (with an associated huge social burden 
in terms of healthcare expenditure and lost productivity11), is a 
target of interest for treating tobacco addiction.  The pyridone-
based cytisine (Tabex®) 6a12, as well as the structurally related 
varenicline (Chantix®)13, target the 42 nAChR providing the 
basis of a smoking cessation therapy. 
 
Figure 1 (-)-Cytisine 6a, varenicline, and CC4 7. C(10) within the pyridone 
moiety is indicated. 
In their 2017 paper,4 Hirano and Miura described the borylation 
of N-Boc cytisine 6e (see below), and here we wish to report our 
independent work in this area and an extension to more complex 
cytisine-based ligands.   
We have evaluated (–)-cytisine 6a as well as a series of 
derivatives, including N-Boc cytisine 6e and CC4 7, as substrates 
for Ir-catalyzed borylation with the objective of gaining access to 
C(10).  CC4 7 is a cytisine-based dimer ligand where the ability to 
access C(10) was of particular interest given this ligand’s 
nicotinic profile.  In 2013 Gotti and Sparatore reported CC4 7 as 
a partial agonist for both the 42 and 62 nAChR subtypes and 
suggested an improved profile for smoking cessation due to the 
great selectivity displayed by CC4 for 2-containing nAChR 
subtypes.14 
Our hypothesis, based on crystallographic data based on cytisine 
and varenicline bound to acetylcholine binding protein 
(AChBP)15, was that substitution at C(10) provides an 
opportunity to interact with the variable (complementary) 
region of the nAChR, which is associated with subtype 
differentiation.16  Previous work by Kozikowski and Kellar, as 
well ourselves, had generated C(10)-substituted variants of 
cytisine.17  However, these involved lengthy synthetic sequences 
that limited the range of variation that was accessible.  Further, 
this earlier work gave racemic products, which is problematic 
especially when contemplating construction of dimeric ligands 
based on CC4.  
In this paper, we have evaluated two approaches to the synthesis 
of C(10) modified variants of CC4 7: (i) C–H activation of cytisine 
to enable access to a C(10)-modified “monomer” unit 
(e.g. bromide 9), dimer formation (via N-alkylation) ) followed by 
further elaboration; and (ii) direct and double C–H activation at 
C(10) of CC4 7, followed by further functional group 
manipulation.  
The first approach required C–H activation of (–)-cytisine 6a, 
itself an effective substrate for Ir-catalyzed borylation 
(Scheme 2). Complete conversion (as judged by 1H NMR) did 
require an excess (1.5 equivalents) of B2pin2, however, isolation 
and purification of the product C(10) boronate ester 8a proved 
problematic. N-Methyl cytisine 6b is also an efficient substrate, 
however, N-benzyl cytisine 6c and N-Cbz cytisine 6d showed 
competing borylation within the aryl moiety of the N-protecting 
group; it is interesting to compare this to the reactivity of 
pyridone 1d. Further details of this study, including optimization 
of key reaction parameters, are available in the Supporting 
Information. 
 
Scheme 2 Site selective Ir-catalyzed borylation of (‒)-cytisine 6a, N-substituted 
cytisine derivatives 6b-d, and N-Boc cytisine 6e. 
In common with Hirano and Miura, we observed very efficient 
Ir-catalyzed borylation of N-Boc cytisine 6e (Scheme 2). In our 
hands, and using dtbpy as the preferred ligand in combination 
with 0.7 equivalents of B2pin2, we achieved essentially 
quantitative borylation of 6e to give 8e.  This was completely 
selective for C(10) and was readily scaled (to 5 grams, 17 mmol 
of 6e).  This result compares to 77% yield (on a 0.2 mmol scale, 
but using a different pyridyl ligand) reported earlier.4  Isolation 
of (crude) 8e was straightforward with no requirement for any 
further purification in terms of the use of this Bpin intermediate 
in subsequent manipulations. 
Boronate 8e was converted efficiently to 10-bromocytisine 9 
(with concomitant N-Boc cleavage occurring under the Cu-
mediated conditions used) and dimer formation using 
1,2-dibromoethane provided the CC4-based bisbromide 10 in 
good (70%) overall yield (Scheme 3).  Bisbromide 10 was a key 
intermediate for accessing a range of C(10)-substituted CC4 
variants (see below). 
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Scheme 3 Synthesis of 10-bromo CC4 10 via C(10) functionalization of N-Boc 
cytisine 8e followed by dimer formation based on 10-bromocytisine 9. 
Ir-catalyzed borylation of CC4 7, so double C-H activation at 
C(10), offers the advantage of more direct access to bisbromide 
10 and this proceeds smoothly (Scheme 4).   
 
Scheme 4 Double C-H activation of CC4 7; use of bisbromide 10 and 
bisboronate 11 to generate a series of C(10) substituted CC4 ligands 12a-i. 
Table 2 CC4 derivatives 12a-i via modification of 10 or 11. 
10-substituent (Y) Reaction conditions (% yield) 
12a[a] Y = CN Pd(PPh3)4, Zn(CN)2, DMF, 80 °C (88%) 
12b[a] Y = Me PdCl2(PPh3)2, Me4Sn, PhMe, 100 °C (83%) 
12c[a] Y = 4-MeC6H5 
PdCl2(PPh3)3, 4-TolB(OH)2, K2CO3, THF/H2O, 
80 °C (91%) 
12d[a] Y = NHAc[c] 
Pd(OAc)2, Xantphos, MeCONH2, Cs2CO3, 
dioxane (71%) 
12e[a] Y = NMe2[c] 
Pd(OAc)2, BINAP, HNMe2, NaOtBu, PhMe, 65 °C 
(71%) 
12f[a]  
 
Pd(OAc)2, BINAP, morpholine, NaOtBu, PhMe, 
100 °C (82%) 
12g[a] Y = CO2Me[c] 
Pd(OAc)2 (40 mol%), dppp, Et3N, CO, 
DMF/MeOH (0.1 M in 10), 80 °C (85%) 
12h[a] Y= CH=CHCO2Et[c] 
Pd2(dba)3, P(tBu)3, Cy2NMe, ethyl acrylate, 
dioxane (72%) 
12i[b] Y= OH[c] NaOH, 30% H2O2 (54%) 
[a]Prepared from bisbromide 10. [b]Prepared from bisboronate 11. [c]Products 
were isolated as the HCl salts. 
The transformation of CC4 7 (likely due to the presence of two 
basic amine centers) required an excess of B2pin2 
(2.80 equivalents) to achieve full conversion. However, workup 
was particularly straightforward and simply involved washing 
the crude (solid) product with diethyl ether.  This served to 
remove the excess of B2pin2 as well as other byproducts, 
providing 11 with a high level of purify and in essentially 
quantitative yield.  Bisboronate 11 was then readily and 
efficiently converted to the key bisbromide 10.  Both bisbromide 
10 and bisboronate ester 11 are of value and have been applied 
to generate a representative series of CC4 derivatives 12a-i 
(Scheme 4, Table 2).  Pd(0) catalyzed C-C bond formation 
provides the bis(cyano), bis(methyl)18 and the Suzuki cross 
coupled products 12a-c. respectively.  Transformations of 
bromide 10 also encompassed amidation (to give 12d) and 
amination (to give 12e and 12f), as well as carbonylation (to give 
12g) and Heck coupling (to give 12h) reactions.  We have 
evaluated use of Cu(I)-based amidation (to prepare 12d) but 
reaction of bisbromide 10 with acetamide and CuI (with TMEDA) 
led to the formation of an insoluble solid suggestive of a complex 
being formed between 10 and Cu(I). 
The use of bisboronate 11 to access C(10)-functionalised CC4 
derivatives was exemplified by direct oxidation of 11, leading to 
the bishydroxy ligand 12i in 54% yield.  Further studies in this 
area are underway but bisboroate ester 11 has been successfully 
used in Suzuki cross couplings reactions involving aryl halides. 
In summary, and with full acknowledgement to the recent work 
of Hirano and Miura,4 we have also successfully applied iridium-
catalyzed borylation to 2-pyridones, with our focus around 
biologically important substrates exemplified by cytisine 6a and 
CC4 7. Pyridones are generally excellent substrates for this mode 
of C-H activation although our experience is that NH pyridones 
(as in 1a) are less effective.  In addition, the presence of a basic 
(amine) center (as in 6a and 7) does tend to require an excess of 
B2pin2 for complete conversion.  Nevertheless, and given 
exceptionally clean conversions, product isolation is 
straightforward and the crude boronate esters (e.g. 11) are very 
effective as substrates for downstream functionalisation.  Details 
of receptor binding studies (including nicotinic subtype 
selectivities) and full agonist functional characteristics of the 
novel CC4 ligands described here will be reported in due course. 
The experimental section has no title; please leave this line here. 
All reagents were purchased from commercial suppliers and used without 
further purification unless otherwise stated. Anhydrous solvents were 
obtained by distillation using standard procedures or by using the 
Anhydrous Engineering Ltd. double alumina and alumina-copper 
catalyzed drying columns. Reactions requiring anhydrous conditions 
were run under an atmosphere of dry nitrogen; glassware and needles 
were flamed-dried prior to use or placed in the oven (150 °C) for at least 
2 h and allowed to cool either in a desiccator, under vacuum, or an 
atmosphere of nitrogen. Thin layer chromatography was performed using 
aluminium backed 60 F254 silica plates. Visualisation was achieved by UV 
fluorescence or a basic KMnO4 or ninhydrin solution and heat. Flash 
column chromatography was performed on silica gel (Aldrich 40-63 µm, 
230-400 mesh) and reverse phase chromatography was performed on an 
automated Biotage IsoleraTM Spektra Four using gradient elution on 
pre-packed Biotage® C18 columns. Infrared spectra were recorded using 
a Perkin Elmer Spectrum One FT-IR Spectrometer as solids or neat films 
in the range of 600-4000 cm-1. NMR spectra were recorded using either a 
Varian 400 MHz or 500 MHz, or JEOL ECP 400 MHz spectrometer. 
Chemical shifts are quoted in parts per million, coupling constants are 
given in Hz to the nearest 0.5 Hz. 1H and 13C NMR spectra are referenced 
to the appropriate residual peak. DEPT 135, COSY, HSQC and HMBC were 
used where necessary in assigning NMR spectra. Melting points were 
determined using Reichert melting point apparatus. Mass spectra were 
determined by the University of Bristol mass spectroscopy service by 
either chemical ionisation (CI+), electrospray ionization (ESI+) or electron 
impact (EI+) using a Bruker Daltonics Apex IV spectrometer.  
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One-pot iridium-catalyzed borylation of 2-pyridones and 
subsequent bromination; General Procedure 1. 
A Schlenk tube was charged with the 2-pyridone substrate (1.0 mmol) [in 
the case of a liquid substrate, this was added neat after the solvent], 
[Ir(cod)(OMe)]2 (6.6 mg, 0.01 eq), 4,4’-di-tert-butyl-2,2’-dipyridyl 
(5.4 mg, 0.02 eq) and bis(pinacolato)diboron (178 mg, 0.70 eq). 
After purging with nitrogen, deoxygenated and dry THF (1.4 mL) was 
added and the reaction mixture was heated at reflux for 48 h (in cases 
where full conversion occurred after 24 h, the reaction was halted at that 
time). The volatile materials were then removed under reduced pressure 
and the crude product was dissolved in MeOH (2.5 mL) and a solution of 
CuBr2 (670 mg, 3.0 mmol) in H2O (2.5 mL) was added. The reaction 
mixture was heated at 80 °C for 18 h under air, cooled to r.t., diluted with 
NH4OH (5 mL, 15% aq.) and extracted with DCM (5 x 5 mL). 
The combined extracts were dried (MgSO4), filtered and concentrated in 
vacuo. Purification of the crude reaction mixture by flash column 
chromatography on silica gel afforded the desired product.  
Table 1 shows the product distributions of 2-5 but no attempt was made 
to optimize monosubstitution (vs disubstitution) in the case of 1b or 1c.  
Tandem borylation/bromination of 1-methylpyridin-2(1H)-one 
(1b). 
According to General Procedure 1, analysis of the 1H NMR of the crude 
reaction mixture showed a conversion of 100%. Products 5-bromo-1- 
methylpyridin-2(1H)-one (3b), 4-bromo-1-methylpyridin-2(1H)-one 
(2b), 4,6-dibromo-1- methylpyridin-2(1H)-one (4b) and 3,5-dibromo-1-
methylpyridin-2(1H)-one (5b) were generated in a 35:5:39:21 ratio.  
Purification by flash column chromatography on silica gel 
(n-Hexane-EtOAc, 70:30 to EtOAc, 100%) gave: 
An inseparable 95:5 mixture of 5-bromo-1-methylpyridin-2(1H)-one 
(3b) and 4-bromo-1-methylpyridin-2(1H)-one (2b) (71 mg, 38%) as an 
orange oil. 
Data for 2b (minor component):  
Rf = 0.24 (EtOAc). 
1H NMR (400 MHz, CDCl3): δ = 7.11 (d, J = 7.5 Hz, 1 H), 6.79 (d,  J = 2.0 Hz, 
1 H), 6.28 (dd, J = 2.0, 7.5 Hz, 1 H), 3.50 (s, 3 H). The spectroscopic 
properties of this compound were consistent with data available in 
literature.19a 
Data for 3b (major component):  
Rf = 0.24 (EtOAc). 
1H NMR (400 MHz, CDCl3): δ = 7.39 (d, J = 2.5 Hz, 1 H), 7.33 (dd, J = 2.5, 
9.5 Hz, 1 H), 6.46 (d, J = 9.5 Hz, 1 H), 3.50 (s, 3 H). The spectroscopic 
properties of this compound were consistent with data available in 
literature.19a 
4,6-Dibromo-1-methylpyridin-2(1H)-one (4b) (58 mg, 22%) as an 
off-white solid; Rf  = 0.59 (EtOAc).  
IR (neat): 3111, 2922, 2851, 1650, 1566, 1495 cm-1.  
1H NMR (400 MHz, CDCl3): δ = 6.75 (s, 1 H), 6.66 (s, 1 H), 3.68 (s, 3 H).  
13C NMR (100 MHz, CDCl3):  δ = 161.5, 134.8, 128.3, 120.7, 114.4, 36.4.  
HRMS-ESI: m/z [M + H]+ calcd for C6H679Br2NO: 265.8811; found: 
265.8799. 
3,5-Dibromo-1-methylpyridin-2(1H)-one (5b) (28 mg, 11%) as 
an -whitewhite solid solid; Rf = 0.51 (EtOAc). 
1H NMR (400 MHz, CDCl3): δ = 7.77 (d, J = 2.0 Hz, 1 H), 7.43 (d, J = 2.0 Hz, 
1 H), 3.58 (s, 3 H). 
13C NMR (100 MHz, CDCl3): δ = 158.0, 143.8, 137.5, 117.4, 96.5, 39.0. The 
spectroscopic properties of this compound were consistent with the data 
available in literature.19b 
Tandem borylation/bromination reaction of 1-butylpyridin-2(1H)-
one (1c). 
According to General Procedure 1, analysis of the 1H NMR of the crude 
reaction mixture showed a conversion of ≥90%. Products 5-bromo-1-
butylpyridin-2(1H)-one (3c), 4-bromo-1-butylpyridin-2(1H)-one (2c), 
4,6-dibromo-1-butylpyridin-2(1H)-one (4c) and 3,5-dibromo-1-
butylpyridin-2(1H)-one (5c) were generated in a 53:26:6:15 ratio. 
Purification by flash chromatography on silica gel (n-Hexane-EtOAc, 
75:25) gave: 
3,5-Dibromo-1-butylpyridin-2(1H)-one (5c) (31 mg, 10%) as a yellow 
oil; Rf = 0.38 (n-Hexane-EtOAc, 70:30).  
IR (neat): 2957, 2929, 1646, 1587, 1514, 1436, 1373, 1215, 1124, 847, 
756, 711 cm-1.  
1H NMR (400 MHz, CDCl3): δ = 7.74 (d, J = 2.5 Hz, 1 H), 7.37 (d, J = 2.5 Hz, 
1 H), 3.93 (t, J = 7.5 Hz, 2 H), 1.75-1.67 (m, 2 H), 1.39-1.30 (m, 2 H), 0.93 (t, 
J = 7.5 Hz, 3 H). 
13C NMR (100 MHz, CDCl3): δ = 157.5, 143.5, 136.8, 117.8, 96.4, 51.4, 31.1, 
19.8, 13.6. 
HRMS-ESI: m/z [M + H]+ calcd for C9H1279Br2NO: 307.9280; found: 
307.9279. 
An inseparable mixture 68:32 of 5-bromo-1-butylpyridin-2(1H)-one 
(3c) and 4-bromo-1-butylpyridin-2(1H)-one (2c) (158 mg, 69%) as a 
yellow oil. 
HRMS-ESI: m/z [M + H]+ calcd for C9H1379BrNO: 230.0175; found: 
230.0175. 
Data for 2c (minor component):  
Rf = 0.22 (n-Hexane-EtOAc, 70:30).  
1H NMR (400 MHz, CDCl3): δ = 7.08 (d, J = 7.5 Hz, 1 H), 6.76 (d, J = 2.0 Hz, 
1 H), 6.28 (dd, J = 2.0, 7.5 Hz, 1 H), 3.93 (t, J = 7.5 Hz, 2 H), 1.75-1.67 (m, 
2 H), 1.39-1.30 (m, 2 H), 0.93 (t, J = 7.5 Hz, 3 H). 
13C NMR (100 MHz, CDCl3): δ = 161.2, 137.3, 135.0, 123.0, 110.0, 49.4, 
31.1, 19.8, 13.6.  
Data for 3c (major component):  
Rf = 0.17 (n-Hexane-EtOAc, 70:30). 
1H NMR (400 MHz, CDCl3): δ = 7.35 (d, J = 2.5 Hz, 1 H), 7.28 (dd, J = 2.5, 
9.5 Hz, 1 H), 6.43 (d, J = 9.5 Hz, 1 H), 3.87 (m, 2 H), 1.71-1.62 (m, 2 H), 
1.38-1.27 (m, 2 H), 0.93-0.88 (m, 3 H).  
13C NMR (100 MHz, CDCl3): δ = 160.9, 142.1, 137.3, 122.2, 97.6, 49.8, 31.3, 
19.8, 13.6.  
5-Bromo-1-benzylpyridin-2(1H)-one (3d) and 4-bromo-1-
benzylpyridin-2(1H)-one (2d).  
Prepared from 1-benzylpyridin-2(1H)-one (1d) using General 
Procedure 1. Analysis of the 1H NMR of the crude product showed a 
conversion of ≥90% and a 65:35 ratio of 5-bromo-1-benzylpyridin-2(1H)-
one (3d) and 4-bromo-1-benzylpyridin-2(1H)-one (2d) respectively.  
Purification by flash column chromatography on silica gel 
(n-Hexane-EtOAc, 75:25) gave: 
An inseparable mixture 65:35 of 5-bromo-1-benzyylpyridin-2(1H)-one 
(3d) and 4-bromo-1-benzyylpyridin-2(1H)-one (2d) (219 mg, 83%) as 
a pale yellow oil.  
HRMS-ESI: m/z [M + H]+ calcd for C12H1179BrNO: 264.0019; found: 
264.0014. 
Data for 2d (minor component): 
1H NMR (400 MHz, CDCl3): δ = 7.46-7.21 (m, 5 H), 7.10 (d, J = 7.0 Hz, 1 H), 
6.83 (s, 1 H), 6.50 (d, J = 10.0 Hz, 1 H), 5.06-4.98 (m, 2 H).  
Data for 3d (major component): 
1H NMR (400 MHz, CDCl3): δ = 7.46-7.21 (m, 7 H), 6.51 (d, J = 10.0 Hz, 1 H), 
5.07 (s, 2 H). The spectroscopic properties of this compound were 
consistent with the data available in literature.19c 
Iridium-catalyzed C‒H borylation of (‒)-cytisine (6a).  
Synthesis of 10-(Bpin)cytisine (8a). 
A Schlenk tube was charged with (‒)-cytisine (6a) (190 mg, 1.0 mmol), 
[Ir(cod)(OMe)]2 (6.6 mg, 0.01 eq), 4,4’-2,2’-di-tert-butylbispyridyl 
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(5.4 mg, 0.02 eq) and bis(pinacolato)diboron (380 mg, 1.50 eq) and was 
placed under vacuum and backfilled with nitrogen for three times. THF 
(1.4 mL) was added and the reaction mixture was heated at reflux for 24 h. 
After this time, the volatile materials were removed under reduced 
pressure and 8a, which was unstable to silica chromatography, was 
partially characterized without further purification and obtained as a 
brown foam.  
1H NMR (500 MHz, CDCl3): δ = 6.88 (d, J = 1.0 Hz, 1 H), 6.27 (s, 1 H), 4.11 
(d, J = 15.5 Hz, 1 H), 3.86 (dd, J = 6.5, 15.5 Hz, 1 H), 3.15-2.78 (m, 5 H), 3.21 
(s, 1 H), 1.94-1.91 (m, 2 H), 1.23 (s, 12 H).  
 13C NMR (125 MHz, CDCl3): δ = 163.1, 149.2, 124.1, 108.8, 84.4, 82.7, 53.3, 
52.3, 49.6, 35.1, 27.5, 25.5, 14.5.  
Iridium-catalyzed C‒H borylation of N-Boc cytisine (6e).  
Synthesis of N-Boc 10-(Bpin)cytisine (8e). 
A Schlenk tube was charged with N-Boc cytisine (6e) (290 mg, 1.0 mmol), 
[Ir(cod)(OMe)]2 (6.6 mg, 0.01 eq), 4,4’-di-tert-butyl-2,2’-dipyridyl 
(5.4 mg, 0.02 eq) and bis(pinacolato)diboron (178 mg, 0.70 eq) and was 
placed under vacuum and backfilled with nitrogen for three times. THF 
(1.4 mL) was added and the reaction mixture was heated at reflux for 18 h. 
After this time, 1H NMR showed essentially 100% conversion, the volatile 
materials were removed under reduced pressure without external 
heating.  The crude product 8e was shown to be essentially pure by 
1H NMR. Simple trituration of crude 8e in Et2O removed the excess of 
B2pin2 as well as other related byproducts, providing 8e in quantitative 
yield in a high level of purity as a pale yellow foam; Rf = 0.23 (DCM-MeOH, 
95:5).  
 
IR (neat): 3433, 2977, 1688, 1657, 1563, 1423 cm-1.  
1H NMR (400 MHz, CDCl3): δ = 6.85 (s, 1 H), 6.31 (s, 1 H), 4.34-4.10 (m, 
3 H), 3.80 (dd, J = 6.5, 15.5 Hz, 1 H), 3.07-2.91 (m, 3 H), 2.41 (s, 1 H), 1.95-
1.88 (m, 2 H), 1.41-1.09 (m, 21 H).  
13C NMR (100 MHz, CDCl3): δ = 162.9, 154.6/154.3 (rotamers), 
147.9/147.5 (rotamers), 124.4, 109.3/108.8 (rotamers), 84.4, 82.6/80.3, 
79.7/75.0 (2 C, rotamers), 51.7/50.6/50.3/49.2 (2 C, rotamers), 48.9, 
34.7, 28.0 (4 C), 27.5, 26.1, 24.8/24.6 (3 C, rotamers); C-Bpin was not 
observed.  
11B NMR (96.4 MHz, CDCl3): δ = 28.94 (br s).  
HRMS-ESI: m/z [M + H]+ calcd for C22H33BN2NaO5: 439.2379; found: 
439.2373.  
The spectroscopic properties of this compound were consistent with the 
data reported by Hirano and Miura.4   
10-Bromocytisine 9 
A Schlenk tube was charged with N-Boc cytisine 6e (2.90 g, 10 mmol), 
[Ir(cod)(OMe)]2 (66 mg, 1 mol%), 4,4’-di-tert-butyl-2,2’-bispyridine (54 
mg, 2 mol%), and bis(pinacolato)diboron (1.78 g, 7.0 mmol). After purging 
with N2, THF (14 mL) was added and the reaction mixture was heated at 
reflux for 24 h. The solution was cooled to r.t. and concentrated in vacuo 
without external heating to give crude 8e, which was used directly in the 
next step without further purification.  
To a solution of crude 8e in MeOH (25 mL), was added a solution of 
copper(II)bromide (6.70 g, 30 mmol) in water (25 mL). The reaction 
mixture was stirred at 80 °C for 24 h under air. NH4OH (50 mL, 15% aq. 
sol.) was added, and the aqueous phase was extracted with DCM (3 × 50 
mL). The combined organic phases were concentrated in vacuo andthe 
residue was distributed between HCl (50 mL, 3 M aq. sol.) and DCM (50 
mL). The aqueous phase was washed with DCM (2 × 50 mL), basified with 
NH4OH (conc.) until pH = 10 and extracted with DCM (5 × 50 mL). The 
combined organic phases were dried (Na2SO4), filtered, and concentrated 
in vacuo to give 9 (2.28 g, 85%) as a colourless solid, mp 153 °C (DCM-
MeOH); Rf = 0.20 (DCM-MeOH, 90:10). 
IR (neat): 3335, 3061, 2934, 2791, 2741, 1622, 1531 cm-1.   
1H NMR (400 MHz, CDCl3): δ = 1.46 (s, 1 H), 1.94 (s, 2 H), 2.33 (m, 1 H), 
2.87 (m, 1 H), 2.97 – 3.10 (m, 4 H), 3.83 (dd, J = 15.5, 6.5 Hz, 1 H), 4.04 (d, 
J = 15.5 Hz, 1 H), 6.17 (d, J = 2.0 Hz, 1 H), 6.67 (d, J = 2.0 Hz, 1 H). 
13C NMR (100 MHz, CDCl3): δ = 26.2, 27.6, 35.5, 49.8, 52.9, 53.7, 108.8, 
118.7, 135.0, 151.6, 162.5. 
HRMS-ESI: m/z [M + H]+ calcd for C11H1479BrN2O: 269.0284, found: 
269.0289. 
Bromide 9 was previously reported by Durkin using a very different 
approach and only as the racemate.17c 
1,2-Bis(10-bromo-N-cytisinyl)ethane 10 
(a) via dimer formation using bromide 9 
A solution of bromide 9 (2.28 g, 8.40 mmol) and K2CO3 (934 mg, 6.72 
mmol) in toluene (4.2 mL) containing 1,2-dibromoethane (0.40 mL, 4.20 
mmol) was heated in a re-sealable tube at 110 °C for 24 h. After cooling, 
the solution was filtered through Celite® and washed with MeOH. 
Purification of the residue by flash column chromatography [DCM-MeOH-
NH4OH, 95:5:0.5] gave bisbromide 10 (1.95 g, 82%) as a pale yellow solid.  
(b) via double C–H activation of CC4 7 
A Schlenk tube was charged with CC4 7 (168 mg, 0.41 mmol), 
[Ir(cod)(OMe)]2 (11 mg, 0.04 eq), 4,4’-di-tert-butyl-2,2’-dipyridyl (8.8 mg, 
0.08 eq) and bis(pinacolato)diboron (293 mg, 2.8 eq) and was placed 
under vacuum and backfilled with nitrogen for three times. THF (2.0 mL, 
0.7 M) was added and the reaction mixture was heated at reflux for 20 h. 
After this time 1H NMR showed essentially 100% conversion.  The volatile 
materials were removed under reduced pressure without external 
heating and simple trituration (washing) of crude product using Et2O 
provided 11 (270 mg, 100%) as a pale yellow solid; m.p. = 159-162 °C.  
 
IR (neat): 2936, 1652, 1562, 1333, 1142, 847, 703 cm-1.  
1H NMR (500 MHz, CDCl3): δ = 6.86 (s, 2 H), 6.23 (s, 2 H), 3.98 (d, 
J = 15.5 Hz, 2 H), 3.84 (dd, J = 7.0 15.5 Hz, 2 H), 2.82 (s, 4 H), 2.73 (m, 2 H), 
2.35 (s, 2 H), 2.27-2.11 (m, 8 H), 1.80 (d, J = 12.5 Hz, 2 H), 1.69 (m, 2 H), 
1.35 (s, 24 H).  
  
13C NMR (126 MHz, CDCl3): δ = 163.0, 150.5, 123.7, 107.9, 84.3, 60.4, 60.1, 
55.2, 50.1, 35.5, 28.0, 25.4, 24.8, 24.6.  
 
The bisboronate 11 (prepared above) was dissolved in MeOH (2.5 mL) 
and the solution was cooled to 0 °C. A solution of CuBr2 (550 mg, 2.47 
mmol) in water (2.5 mL) was added and the reaction mixture was stirred 
for 48 h under air before being quenched by the addition of NH4OH (15 
mL, 15% aq. sol). The aqueous phase was extracted with DCM (3 x 25 mL) 
and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo. Purification of the crude product by flash column 
chromatography afforded bisbromide 10 (185 mg, 79%) as a pale yellow 
solid; mp 173 °C (DCM-n-Hexane), Rf = 0.31 (DCM-MeOH, 95:5). 
[α]D24 = –108 (c 1.0, MeOH). 
IR (neat): 2935, 2785, 1634, 1534, 811 cm-1.  
1H NMR (400 MHz, CDCl3): δ = 1.68 (d, J = 13.0 Hz, 2 H), 1.80 (d, J = 13.0 
Hz, 2 H), 2.09 – 2.26 (m, 6 H), 2.26 – 2.38 (s, 4 H), 2.67 (d, J = 11.5 Hz, 2 H), 
2.76 (s, 2 H), 2.83 (d, J = 11.5 Hz, 2 H), 3.75 (dd, J = 15.0, 6.5 Hz, 2 H), 3.92 
(d, J = 15.0, 2 H), 6.12 (d, J = 2.0, 2 H), 6.65 (d, J = 2.0, 2 H). 
13C NMR (101 MHz, CDCl3): δ = 25.8, 27.9, 35.7, 50.2, 55.2, 60.2, 60.6, 
108.5, 118.6, 134.7, 152.3, 162.5.  
HRMS-ESI: m/z [M + H]+ calcd for C24H2979Br2N4O2: 563.0652, found: 
563.0647. 
1,2-Bis(10-cyano-N-(–)-cytisinyl)ethane 12a 
A Schlenk tube was charged with bromide 10 (169 mg, 0.30 mmol), 
Pd(PPh3)4 (27 mg, 0.08 eq) and zinc cyanide (42 mg, 1.2 eq), placed under 
vacuum and backfilled with nitrogen for three times. DMF (1 mL, 0.8 M) 
was added, and the reaction mixture was stirred at 80 °C for 24 h. The 
solvent was removed in vacuo. Purification of the crude product by flash 
column chromatography [DCM-MeOH, 2% MeOH] afforded 12a (119 mg, 
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88%) as a pale-yellow solid, m.p. = 168-171 °C, Rf = 0.11 [DCM-MeOH, 2% 
MeOH].  
IR (neat): 3350, 1647, 1562, 1534, 1473, 2236 cm-1.  
1H NMR (500 MHz, CDCl3): δ = 6.68 (d, J = 2.0 Hz, 2 H), 6.02 (d, J = 2.0 Hz, 
2 H), 3.92 (d, J = 15.0 Hz, 2 H), 2.09 (dd, J = 6.5, 15.0 Hz, 2 H), 2.88 (s, 2 H), 
2.81 (d, J = 11.5 Hz, 2 H), 2.69 (d, J = 11.5, 2 H), 2.36 (s, 2 H), 2.20 (m, 8 H), 
1.83 (d, J = 15.0 Hz, 2 H), 1.72 (d, J = 15.0 Hz, 2 H).  
13C NMR (125 MHz, CDCl3): δ = 161.4, 154.4, 122.6, 121.1, 116.3, 103.6, 
60.3, 60.0, 55.1, 50.6, 35.6, 27.6, 25.3.  
HRMS-ESI: m/z [M + Na]+ calcd for C26H28N6NaO2: 479.2166, found: 
479.2164. 
1,2-Bis(10-Methyl-N-cytisinyl)ethane 12b 
A Schlenk tube was charged with bromide 10 (175 mg, 0.31 mmol), 
PdCl2(PPh3)2 (22 mg, 0.10 eq) and it was placed under vacuum and 
backfilled with nitrogen for three times. The solids were dissolved in 
toluene (2 mL), tetrametyltin (0.22 mL, 5.0 eq) was added and the solution 
was heated at 100 °C for 24 h. The mixture was cooled, EtOAc (15 mL) was 
added and the solution was filtered through celite® and concentrated. 
Purification of the crude product by flash column chromatography 
[DCMMeOH, 5% MeOH] afforded 12b (111 mg, 83%) as a colourless foam, 
Rf = 0.47 [DCM-MeOH, 5% MeOH].  
IR (neat): 3406, 2931, 1645, 1539, 1471, 1367, 1136, 617 cm-1.  
1H NMR (500 MHz, CDCl3): δ = 6.23 (s, 2 H), 5.74 (s, 2 H), 3.95 (dd, 
J = 15.0 Hz, 2 H), 3.78 (dd, J = 7.0, 17.0 Hz, 2 H), 2.83 (d, J = 10.0 Hz, 2 H), 
2.74 (s, 2 H), 2.66 (d, J = 10.0 Hz, 2 H), 2.34 (s, 2 H), 2.25 (m, 2 H), 2.21-
2.11 (m, 12 H), 1.78 (d, J = 12.0 Hz, 2 H), 1.67 (d, J = 12.0 Hz, 2 H).   
13C NMR (125 MHz, CDCl3): δ = 163.5, 150.6, 149.7, 115.2, 106.8, 60.6, 
60.1, 55.0, 49.7, 35.5, 28.0, 25.6, 21.2. 
HRMS-ESI: m/z [M + Na]+ calcd for C26H34N4NaO2: 457.2574, found: 
457.2574. 
1,2-Bis(10-p-tolyl-N-cytisinyl)ethane 12c 
A Schlenk tube was charged with 10 (282 mg, 0.50 mmol), PdCl2(PPh3)2 
(35 mg, 50 μmol, 10 mol%), p-tolyl boronic acid (163 mg, 1.20 mmol) and 
K2CO3 (347 mg, 2.50 mmol). After purging with nitrogen, THF (5.0 mL) 
and water (1.2 mL) were added and the reaction mixture was heated at 
reflux for 23 h. The solution was cooled to r.t. and distributed between 
DCM(5 mL) and water (5.0 mL), and the aqueous phase was extracted 
with DCM (3 × 5 mL). The combined organic phases were dried (Na2SO4), 
filtered, and concentrated in vacuo. Purification of the residue by flash 
column chromatography [DCM-MeOH-NH4OH, 95:5:0.5] gave 12c 
(266 mg, 91%) as a yellow solid, m.p. > 200 °C (DCM-n-Hexane), Rf = 0.20 
[DCM-MeOH, 95:5]. 
[α]D24 = –120 (c 1.0, MeOH). 
IR (neat): 2933, 2768, 1648, 1564, 809 cm-1.  
1H NMR (400 MHz, CDCl3): δ = 1.70 (d, J = 13.0 Hz, 2 H), 1.83 (d, J = 13.0 Hz, 
2 H), 2.13 (s, 2 H), 2.24 (m, 4 H), 2.37 (m, 10 H), 2.67 (m, 2 H), 2.83 (m, 
4 H), 3.83 (dd, J = 6.5, 15.0 Hz, 2 H), 4.00 (d, J = 15.0 Hz, 2 H), 6.02 (d, 
J = 2.0 Hz, 2 H), 6.60 (d, J = 2.0 Hz, 2 H), 7.17 (d, J = 8.0 Hz, 4 H), 7.34 (d, 
J = 8.0 Hz, 4H).  
13C NMR (101 MHz, CDCl3): δ = 21.3, 26.0, 28.1, 36.0, 50.0, 55.0, 60.2, 60.5, 
103.7, 112.6, 126.6, 129.7, 135.1, 139.2, 150.4, 151.6, 163.8.  
HRMS-ESI: m/z [M + H]+ calcd for C38H44N4O2: 587.3381, found: 587.3366. 
1,2-Bis(10-(N-acetylamino)-N-cytisinyl)ethane hydrochloride salt 
12d 
A Schlenk tube was charged with dibromide 10 (141 mg, 0.25 mmol), 
acetamide (35 mg, 0.60 mmol), Pd(OAc)2 (1 mg, 5 μmol, 2 mol%), 4,5-
bis(diphenylphosphino)-9,9-dimethylxanthene (6 mg, 10 μmol, 4 mol%), 
and Cs2CO3 (244 mg, 0.75 mmol). After purging with nitrogen, 1,4-dioxane 
(0.50 mL) was added and the reaction mixture was stirred at 100 °C for 
20 h. The solution was cooled to r.t. and diluted with DCM (10 mL), filtered 
through Celite®, and concentrated in vacuo. Purification of the residue by 
flash column chromatography [DCM:MeOH:NH4OH, 95:5:0.5 to 92:8:0.8] 
gave 12d (110 mg, 84%) as a colourless solid. The resulting solid was 
dissolved in a solution of HCl in MeOH (0.37 mL, 0.5 M), acetone was 
added (40 mL), and the solution was stirred for 3 h. The precipitate was 
filtered off and dried in vacuo to give the HCl salt of 12d (105 mg, 71%) as 
pale yellow solid, m.p. > 200 °C (MeOH-acetone), Rf = 0.12 [DCM-MeOH, 
90:10]. 
[α]D24 = –122 (c 1.0, MeOH). 
IR (neat): 2933, 2793, 1699, 1640, 1548, 1257, 845, 728 cm-1.  
1H NMR (400 MHz, D2O): δ = 1.66 (s, 4 H), 2.00 – 2.20 (m, 12 H), 2.25 – 
2.35 (m, 4 H), 2.60 (d, J = 11.0 Hz, 2 H), 2.75 – 2.89 (m, 4 H), 3.75 (m, 4 H), 
6.46 (m, 2 H), 6.50 (m, 2 H), 7.17 (m, 2 H). 
13C NMR (101 MHz, D2O): δ = 23.6, 24.5, 27.3, 35.3, 50.3, 54.2, 59.1, 59.7, 
100.0, 101.8, 148.6, 153.4, 165.3, 173.6.  
HRMS-ESI: m/z [M + H]+ calcd for C28H37N6O4: 521.2871, found: 521.2859. 
1,2-Bis(10-(N,N’-dimethylamino)-N-cytisinyl)ethane hydrochloride 
salt 12e 
A sealed tube with screwed cap was charged with dibromide 10 (141 mg, 
0.25 mmol), Pd(OAc)2 (6 mg, 25 μmol, 10 mol%), BINAP (21 mg, 35 μmol, 
14 mol%) and NaOtBu (120 mg, 1.25 mmol). After purged with N2, toluene 
(1.7 mL) and dimethylamine (0.50 mL, 1 M in THF, 0.50 mmol) were 
added. The tube was sealed and the reaction mixture was stirred at 65 °C 
for 20 h. The solution was cooled to r.t. and distributed between water 
(10 mL) and DCM (10 mL), and the aqueous phase was extracted with 
DCM (4 × 10 mL). The combined organic phases were dried (Na2SO4), 
filtered, and concentrated in vacuo. Purification of the residue by flash 
column chromatography [DCM-MeOH-NH4OH, 95:5:0.5 to 92:8:0.8] gave 
12e (96 mg, 78%) as a pale yellow solid. The resulting solid was dissolved 
in a solution of HCl in MeOH (0.37 mL, 0.5 M), acetone was added (40 mL) 
and the mixture was stirred for 3 h. The precipitate was filtered off and 
dried in vacuo to give the HCl salt of 12e (100 mg, 71%) as pale yellow 
solid, m.p. > 200 °C (MeOH-acetone), Rf = 0.18 [DCM-MeOH, 90:10]. 
[α]D25 = +5 (c 1.0, water). 
IR (neat): 2926, 2800, 1635, 1531, 1331, 1138, 801 cm-1.  
1H NMR (400 MHz, D2O): δ = 1.95 (s, 4 H), 2.71 (s, 2 H), 2.95 (s, 12 H), 3.17 
(dd, J = 1.5, 12.5 Hz, 2 H), 3.24 (dd, J = 1.5, 12.1 Hz, 2 H), 3.37 (m, 6 H), 3.49 
(d, J = 12.5 Hz, 2 H), 3.57 (d, J = 12.5 Hz, 2 H), 3.92 (dd, J = 15.0, 6.0 Hz, 2 H), 
4.00 (d, J = 15.0 Hz, 2 H), 6.31 (s, 2 H), H5 and H5’ were not detected.  
13C NMR (101 MHz, D2O): δ = 22.6, 26.2, 33.0, 39.1, 48.3, 51.7, 57.7, 58.4, 
101.5, 146.7, 157.6, 161.4.  
HRMS-ESI: m/z [M + H]+ calcd for C28H41N6O2: 493.3286, found: 493.3279. 
1,2-Bis(10-morpholino-N-cytisinyl)ethane 12f 
A Schlenk tube was charged with dibromide 10 (141 mg, 0.25 mmol), 
morpholine (87 μL, 1.00 mmol), Pd(OAc)2 (6 mg, 25 μmol, 10 mol%), 
BINAP (21 mg, 35 μmol, 14 mol%) and NaOtBu (120 mg, 1.25 mmol). After 
purged with N2, toluene (1.7 mL) was added and the reaction mixture was 
stirred at 100 °C for 21 h. The solution was distributed between water 
(10 mL) and DCM (10 mL), and the aqueous phase was extracted with 
DCM (4 × 10 mL). The combined organic phases were dried (Na2SO4), 
filtered, and concentrated in vacuo. Purification of the residue by flash 
column chromatography [DCM-MeOH-NH4OH, 95:5:0.5 to 92:8:0.8] gave 
12f (119 mg, 82%) as a pale yellow solid, m.p. > 200 °C (DCM-n-Hexane), 
Rf = 0.18 (DCM-MeOH, 90:10).  
[α]D24 = –38 (c 1.0, MeOH). 
IR (neat): 2926, 2851, 1636, 1530, 1236, 1119, 803 cm-1.   
1H NMR (400 MHz, CDCl3): δ = 1.65 (d, J = 13.0 Hz, 2 H), 1.77 (d, J = 13.0 Hz, 
2 H), 2.16 – 2.26 (m, 8 H), 2.30 (s, 2 H), 2.70 (m, 4 H), 2.82 (m, 2 H), 3.19 
(m, 8 H), 3.67 (dd, J = 7.0, 14.5 Hz, 2 H), 3.77 (t, J = 5.0 Hz, 8 H), 3.88 (d, 
J = 14.5 Hz, 2 H), 5.63 (d, J = 2.5 Hz, 2 H), 5.66 (d, J = 2.5 Hz, 2 H).  
13C NMR (101 MHz, CDCl3): δ = 26.2, 28.0, 36.2, 46.7, 49.2, 55.2, 60.1, 61.0, 
66.5, 94.7, 95.3, 100.0, 151.1, 157.2, 164.5.  
HRMS-ESI: m/z [M + H]+ calcd for C32H45N6O4: 577.34297, found: 
577.3509. 
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Methyl 1,2-bis(N-(-)-cytisinyl)ethane-10-carboxylate hydrochloride 
salt 12g 
A Schlenk flask was charged with dibromide 10 (141 mg, 0.25 mmol), 
trimethylamine (87 μL, 0.62 mmol), 1,3-bis(diphenylphosphino)propane 
(20 mg, 20 mol%) and Pd(OAc)2 (22 mg, 40 mol%). After purging with 
nitrogen, DMF (0.6 mL) and MeOH (0.6 mL) were added, and the flask was 
placed under a CO atmosphere (approx. 1 atm, balloon) and the reaction 
mixture was heated at 80 °C for 20 h. The solution was cooled to r.t., 
filtered through Celite®, and concentrated in vacuo. Purification of the 
residue by flash column chromatography [DCM-MeOH-NH4OH, 95:5:0.5] 
gave 12g (111 mg, 85%) as a dark yellow solid. The resulting solid was 
dissolved in a solution of HCl in MeOH (0.37 mL, 0.5 M in MeOH), acetone 
was added (40 mL) and the mixture was stirred for 3 h. The precipitate 
was filtered off and dried in vacuo to give 12g, (111 mg, 85%) as yellow 
solid, m.p. > 200 °C, (MeOH-acetone), Rf = 0.28 [DCM-MeOH, 95:5). 
[α]D25 = –180 (c 1.0, water). 
IR (neat): 2953, 1720, 1658, 1576, 1545, 1442, 1251, 775 cm-1. 
1H NMR (400 MHz, D2O): δ = 1.98 (s, 4 H), 2.79 (s, 2 H), 3.17 (d, J = 12.5 Hz, 
2 H), 3.25 (d, J = 10.5 Hz, 2 H), 3.33 (s, 4 H), 3.45 (m, 4 H), 3.55 (d, 
J = 12.5 Hz, 2 H), 3.83 (s, 6 H), 3.91 (dd, J = 16.0, 6.5 Hz, 2 H), 4.00 (d, 
J = 16.0 Hz, 2 H), 6.80 (s, 2 H), 6.97 (s, 2 H).  
13C NMR (101 MHz, D2O): δ = 22.4, 26.3, 33.1, 49.0, 51.5, 53.4, 57.6, 58.4, 
107.5, 118.4, 141.32, 148.1, 164.8, 166.5.  
HRMS-ESI: m/z [M + H]+ calcd for C28H35N4O6: 523.2551, found 523.2550. 
Diethyl 1,2-bis(N-(–)-cytisinyl)ethane-10-ethyl acrylate 
hydrochloride salt 12h 
A Schlenk tube was charged with dibromide 10 (141 mg, 0.25 mmol) and 
Pd2(dba)3 (11 mg, 5 mol%), placed under vacuum and backfilled with 
nitrogen for three times.  1,4-dioxane (2.2 mL) was added, followed by 
tri--butylphosphine (0.25 mL, 0.1 M in 1,4-dioxane, 10 mol%), 
dicyclohexylmethylamine (0.12 mL, 0.55 mmol), and ethyl acrylate 
(0.11 mL, 1.00 mmol) respectively. The reaction mixture was stirred at 
room temperature for 24 h. Pd2(dba)3 (11 mg, 5 mol%), tri-tert-
butylphosphine (0.25 mL, 0.1 M in 1,4-dioxane, 10 mol%) and ethyl 
acrylate (0.11 mL, 1.00 mmol) were added butylphosphine (0.25 mL, 0.1 
M in 1,4-dioxane, 10 mol%) and ethyl acrylate (0.11 mL, 1.00 mmol) were 
added and the reaction mixture was stirred further for 24 h. The mixture 
was filtered through Celite® and washed with EtOAc (20 mL), and the 
solvent was removed in vacuo. Purification of the crude product by flash 
column chromatography [CH2Cl2-MeOH-NH4OH, 95:5:0.5] gave a brown 
solid (111 mg, 85%). The resulting solid was dissolved in HCl (0.37 mL, 
0.5 M in MeOH). Acetone was added (40 mL) and the mixture was stirred 
for 3 h. The precipitate was filtered off and dried in vacuo to give 12h (121 
mg, 72%) as a yellow solid; m.p. > 200 °C, Rf = 0.22 [CH2Cl2-MeOH, 95:5]. 
[α]D25 = –75 (c 1.0, water). 
IR (neat): 2945, 1720, 1656, 1574, 1544, 1443, 1253, 1178, 1092 cm-1. 
1H NMR (400 MHz, D2O): δ = 1.22 (t, J = 7.0 Hz, 6 H), 1.91 (s, 4 H), 2.66 (s, 
2 H), 2.95 (m, 4 H), 3.07 (s, 4 H), 3.18 (d, J = 12.0 Hz, 2 H), 3.26 (s, 2 H), 
3.37 (d, J = 12.0 Hz, 2 H), 3.84 (dd, J = 6.5, 16.0 Hz, 2 H), 3.98 (d, J = 16.0 Hz, 
2 H), 4.18 (q, J = 7.0 Hz, 4 H), 6.51 (s, 2 H), 6.52 (d, J = 16.0 Hz, 2 H), 6.54 
(s, 2 H), 7.39 (d, J = 16.0 Hz,2 H).  
13C NMR (101 MHz, D2O): δ = 13.4, 23.0, 26.5, 33.6, 49.2, 52.4, 57.8, 58.9, 
62.3, 106.5, 116.5, 124.3, 141.3, 146.3, 148.6, 164.8, 168.0. 
HRMS-ESI: m/z [M+H]+ calcd for C34H43N4O6: 603.3177, found: 603.3169. 
1,2-Bis(10-hydroxy-N-cytisinyl)ethane hydrochloride salt 12i 
A Schlenk tube was charged with CC4 7 (203 mg, 0.50 mmol), 
[Ir(cod)(OMe)]2 (6.6 mg, 0.02 eq), 4,4’-di-tert-butyl-2,2’-dipyridyl 
(5.4 mg, 0.04 eq) and bis(pinacolato)diboron (177 mg, 1.4 eq) and was 
placed under vacuum and backfilled with nitrogen for three times. THF 
(1.0 mL, 0.5 M) was added and the reaction mixture was heated at reflux 
for 20 h.  After this time 1H NMR showed essentially 100% conversion. 
The solution was allowed to reach r.t. and then cooled to 0 °C.  A solution 
2M NaOH (1.5 mL, 6 eq.) was added followed by the addition of H2O2 
(1.0 mL, 30% w/w in water), the Schlenk tube was removed from the ice 
bath and the reaction mixture was stirred for 24 h. The solvent was 
removed in vacuo. The crude was dissolved in a solution of HCl in MeOH 
(1 mL, 0.5 M) and Et2O (15 mL) was added. The precipitate was filtered 
off and dried under vacuum. Purification by reverse phase 
chromatography using a Biotage SNAP Ultra C18 12g column and gradient 
elution (water to MeCN) afforded 12i (118 mg, 54%) as a colorless solid; 
mp > 200 °C. 
 [α]D20 = –115 (c 6.5, MeOH). 
IR (neat): 2974, 1638, 1543, 1085, 1044, 878, 624. 
1H NMR (500 MHz, MeOD): δ = 5.85 (d, J = 2.5 Hz, 2 H), 5.71 (d, J = 2.5 Hz, 
2 H), 3.88 (d, J = 15.5 Hz, 2 H), 3.73 (dd, J = 15.5, 7.5 Hz, 2 H), 2.89 (d, 
J = 11.0 Hz, 2 H), 2.82 (s, 2 H), 2.72 (d, J = 11.0 Hz, 2 H), 2.38-2.28 (m, 4 H), 
2.26-2.16 (m, 6 H), 1.82 (d, J = 13.5 Hz, 2 H), 1.69 (d, J = 13.5 Hz, 2 H).  
13C NMR (125 MHz, D2O): δ = 167.3, 165.7, 152.9, 99.7, 95.9, 60.2, 59.8, 
54.8, 49.6, 35.6, 28.0, 25.2.  
HRMS-ESI m/z [M+H]+ calcd for C24H30N4NaO4:461.2159, found 461.2137. 
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1. General Experimental Details. 
All reagents were purchase from commercial suppliers and used without further purification 
unless otherwise stated. Anhydrous solvents were obtained by distillation using standard 
procedures or by using the Anhydrous Engineering Ltd. double alumina and alumina-copper 
catalyzed drying columns.  
Reactions requiring anhydrous conditions were run under an atmosphere of dry nitrogen; 
glassware and needles were flamed-dried prior to use or placed in the oven (150 °C) for at 
least 2 h and allowed to cool either in a desiccator, under vacuum, or an atmosphere of 
nitrogen. Thin layer chromatography was performed using aluminium backed 60 F254 silica 
plates. Visualisation was achieved by UV fluorescence or a basic KMnO4 solution and heat.  
Flash column chromatography was performed on silica gel (Aldrich 40-63 µm, 230-400 mesh). 
Infrared spectra were recorded using a Perkin Elmer Spectrum One FT-IR Spectrometer as 
solids or neat films in the range of 600-4000 cm-1.  
NMR spectra were recorded using either a Varian 400 MHz or 500 MHz, or JEOL ECP 400 
MHz spectrometer. Chemical shifts are quoted in parts per million, coupling constants are 
given in Hz to the nearest 0.5 Hz. 1H and 13C NMR spectra are referenced to the appropriate 
residual peak. DEPT 135, COSY, HSQC and HMBC were used where necessary in assigning 
NMR spectra.  
Mass spectra were determined by the University of Bristol mass spectroscopy service by either 
chemical ionisation (CI+), electrospray ionization (ESI+) or electron impact (EI+) using a Bruker 
Daltonics Apex IV spectrometer.  
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2. Optimization studies for the Ir-catalyzed borylation of cytisine derivatives. 
 
Table 1. Ligand and substrate optimization studies. 
 
Entry Substrate Conditions[a] Product %[b] 
1 (–)-Cytisine 6a dtbpy; 1.50 eq. B2pin2; 24 h 
 
100% 
2 (–)-Cytisine 6a Me4phen; 3.00 eq. B2pin2; 24 h 100% 
3 (–)-Cytisine 6a neocuproine; 1.50 eq. B2pin2; 24 h 100% 
4 N-Boc cytisine 6e dtbpy; 0.70 eq. B2pin2; 18 h 
8e (R = Boc) 
100% 
5 
N-Methyl cytisine 
6b 
as entry 4 (R = Me) 98% 
6 N-Bn-cytisine 6c as entry 4 Over-borylation[c] 
7 N-Cbz cytisine 6d as entry 4 
Over-borylation[c] 
88% 
dtbpy = 4,4'-di-tert-butyl-2,2'-dipyridyl; Me4phen = 3,4,7,8-tetramethyl-1,10-phenanthroline; 
neocuproine  = 2,9-dimethyl-1,10-phenanthroline.  
[a] Standard conditions are as shown above.  
[b] Yields shown represent conversion as judged by 1H NMR; purification of the initially-formed 
boronate esters was avoided (and was unnecessary) with full characterization carried out on 
the corresponding 10-bromo derivative.  
[c] 1H NMR indicated competing and unselective borylation in the Bn and Cbz aryl moiety. The 
borylation site within the N-arylated substituent was not determined and an overall solution 
yield (to assess conversion) was only obtained for entry 7. Similar competing C–H insertion 
reactions were also observed with N-Fmoc cytisine (not shown here).   
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Table 2. Solvent screening for the borylation of N-Boc cytisine 6e.  
 
Entry Solvent Temp, Time (h) 1H NMR Conversion (%) 
1 Ethyl acetate 70 °C, 24 h 6 
2 Dioxane 70 °C, 24 h 60 
3 Chloroform 60 °C, 24 h - 
4 Butanone 70 °C, 24 h 16 
5 F3CC6H5 70 °C, 24 h 9 
6 Cyclohexane 70 °C, 24 h 86 
7 THF 70 °C, 18 h 100 
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3. Copies of 1H/13C NMR Spectra. 
1H of a 95:5 mixture of 3b + 2b 
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1H and 13C of 4b 
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1H and 13C of 5b 
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1H and 13C of a 68:32 mixture of 3c + 2c 
 
Supporting Information:  Iridium-catalyzed C–H Borylation of 2-Pyridones 9 
1H and 13C of 5c 
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1H and 13C of a 65:35 mixture of 3d + 2d 
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1H and13C of 10-Bpin-cytisine 8a 
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1H and 13C of N-Boc cytisine 8e 
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11B NMR of N-Boc cytisine 8e 
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1H and 13C of 10-bromocytisine 9 
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1H and 13C of bisbromide 10 
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1H and 13C of bisboronate 11 
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1H and 13C of derivative 12a 
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1H and 13C of derivative 12b 
 
 
  
Supporting Information:  Iridium-catalyzed C–H Borylation of 2-Pyridones 19 
1H and 13C of derivative 12c 
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1H and 13C of derivative 12d (hydrochloride salt) 
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1H and 13C of derivative 12e (hydrochloride salt) 
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1H and 13C of derivative 12f 
 
 
  
Supporting Information:  Iridium-catalyzed C–H Borylation of 2-Pyridones 23 
1H and 13C of derivative 12g (hydrochloride salt) 
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1H and 13C of derivative 12h (hydrochloride salt) 
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1H and 13C of derivative 12i 
 
 
